Polycystic Liver Disease in Kidney Transplant
| Status: | Completed |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease, Gastrointestinal |
| Therapuetic Areas: | Gastroenterology, Nephrology / Urology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 11/18/2012 |
| Start Date: | February 2009 |
| End Date: | August 2012 |
| Contact: | Qi Qian, M.D. |
| Email: | qian.qi@mayo.edu |
| Phone: | 507-284-2511 |
Single Center, Open-label Randomized Prospective Trial: Effect of Sirolimus on Polycystic Liver Disease
The purpose of this study is to see if one kind of immunosuppressive drug has better effects
for the patient's polycystic liver disease than another type. Tacrolimus and Sirolimus are
the two immunosuppressive drugs that will be compared for this study. Both drugs have been
commonly prescribed to prevent rejection.
Inclusion Criteria:
- Adults (> 18 years old) with stage IV or V chronic kidney due to ADPKD
- Primary kidney transplant
- Living or deceased donor kidney transplant
- Estimate total liver volume of 2.5 to 7.5 L
Exclusion Criteria:
- Pediatric patients (< 18 years of age)
- Patients with BMI > 40
- Multi-organ transplant (kidney-liver, etc.)
- ABO-incompatible or positive cross-match recipients
- Patients with severe hyperlipidemia (serum cholesterol > 350 mg/dl or serum
triglycerides > 500 mg/dl)
- Patients with leukopenia (WBC < 3000 10/ml)
- Patients unwilling to return to the transplant center for late follow-up visits
- Patients who are currently pregnant or breast-feeding or who expect to be pregnant
during the study period
- Female patients of child bearing potential and men with sexual partners of child
bearing potential who do not agree to use a medically accepted method of
contraception during the study period
- Patients who are not eligible for Thymoglobulin induction
We found this trial at
1
site
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
Click here to add this to my saved trials
